ClinicalTrials.gg
CompletedNCT02347085Updated Jul 19, 2018Results posted

24-hour Lung Function in Subjects With Moderate to Very Severe COPD After Treatment With PT003 and Placebo MDI

A Phase 3 interventional study of GFF MDI (PT003) and Placebo MDI in COPD, sponsored by Pearl Therapeutics, Inc.. Completed. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2018-07-19.

Sponsored by Pearl Therapeutics, Inc. (part of AstraZeneca) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
43
Allocation
Randomized
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, 1 of them phase 3. Glycopyrrolate · Pulmonary Disease, Chronic Obstructive.

Enrollment
55th of 73
43 · median 152
Started
2015
with 7 others
Phase 3
33 of 73
1 open now
Registered
45th of 73
by date
Lead sponsor
18 of 73
Pearl Therapeutics, Inc.

Among the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, this one is the 55th largest by enrollment, is one of 8 that started in 2015, is one of 33 in phase 3, and was the 45th registered.

Pulmonary Disease, Chronic Obstructive

5,522 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About glycopyrrolate

Glycopyrrolate: first FDA approval 1961 (ROBINUL FORTE), first EMA approval 2012. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing glycopyrrolate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

Randomized, Phase IIIb, Two-period, Two-treatment Double-blind, Multi-center, Crossover Study to Evaluate the 24-hour Lung Function Profile in Subjects with Moderate to Very Severe COPD after 4 Weeks of Treatment with PT003 and Placebo MDI

03

Conditions studied

04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • At least 40 years of age and no older than 80 at Screening
  • Women of non-child bearing potential or negative serum pregnancy test at Screening, and agrees to acceptable methods used consistently and correctly Screening until 14 days after final visit
  • Subjects with an established clinical history of as defined by the American Thoracic Society (ATS)/European Respiratory Society (ERS)
  • Current or former smokers with a history of at least 10 pack-years of cigarette smoking
  • Pre- and post-bronchodilator /FVC ratio of \<0.70
  • Post-bronchodilator FEV1 must be \<80% predicted normal value, calculated using NHANES III reference equations, and the measured FEV1 must also be ≥750 mL if FEV1 \<30% of predicted normal value

Exclusion criteria

Exclusion Criteria:

  • Significant diseases other than , i.e., disease or condition which, in the opinion of the Investigator, may put the subject at risk because of participation in the study or may influence either the results of the study or the subject's ability to participate in the study
  • Women who are pregnant or lactating
  • Subjects, who in the opinion of the Investigator, have a current diagnosis of asthma
  • Subjects who have been hospitalized due to poorly controlled COPD within 3 months prior to Screening or during the Screening Period
  • Subjects who have poorly controlled COPD, defined as acute worsening of COPD that requires treatment with oral or antibiotics within 6 weeks prior to Screening or during the Screening Period
  • Subjects who have uncontrolled hypertension.
  • Subjects who have cancer that has not been in complete remission for at least five years
  • Subjects with abnormal liver function tests defined as , ALT, or total ≥1.5 times at Screening and on repeat testing
  • Subjects with a diagnosis of angle closure glaucoma will be excluded, regardless of whether or not they have been treated. Subjects with a diagnosis of open angle glaucoma who have intraocular pressure controlled with medication(s) are eligible
  • Subjects with symptomatic prostatic hypertrophy that is clinically significant in the opinion of the Investigator. Subjects with a trans-urethral resection of prostate (TURP) or full resection of the prostate within 6 months prior to Screening are excluded from the study
  • Subjects with bladder neck obstruction or urinary retention that is clinically significant in the opinion of the Investigator
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    GFF MDI (PT003)

    Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

    Drug: GFF MDI (PT003)

  • Placebo comparator
    Placebo MDI

    Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

    Drug: Placebo MDI

Interventions

  • DrugGFF MDI (PT003)

    Drug pages: Glycopyrrolate · Formoterol

    Also known as: Glycopyrronium and Formoterol Fumarate Inhalation Aerosol; PT003, Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler (GFF MDI)

  • DrugPlacebo MDI

    Also known as: Placebo Metered Dose Inhaler (MDI) for Glycopyrronium and Formoterol Fumarate Inhalation Aerosol

06

What researchers measure

Primary outcomes

  1. FEV1 AUC0-24 on Day 29

    Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC)0-24 on Day 29

    Time frame: Day 29

Secondary outcomes

  1. FEV1 AUC12-24 on Day 29

    FEV1 AUC12-24 on Day 29

    Time frame: Day 29

  2. FEV1 AUC0-12 on Day 29

    FEV1 AUC0-12 on Day 29

    Time frame: Day 29

  3. Peak Change From Baseline in FEV1 on Day 29

    Peak Change From Baseline in FEV1 following evening Dose on Day 29

    Time frame: Day 29

  4. Peak Change From Baseline in FEV1 on Day 29

    Peak Change From Baseline in FEV1 following the morning dose on Day 29

    Time frame: Day 29

  5. Morning Pre-Dose Trough FEV1 on Day 29

    Morning Pre-Dose Trough FEV on Day 29

    Time frame: Day 29

  6. Morning Pre-Dose Trough FEV1 on Day 30

    Morning Pre-Dose Trough FEV1 on Day 30

    Time frame: Day 30

  7. Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29

    Peak Change from Baseline in Inspiratory Capacity (IC) following the evening dose on Day 29

    Time frame: Day 29

  8. Peak Change From Baseline in IC Following the Morning Dose on Day 29

    Peak Change from Baseline in IC following the morning dose on Day 29

    Time frame: Day 29

07

Results

Posted Apr 19, 2017

Participant flow

This study was conducted at 5 sites in the US from March 2015 to Jun 2015. The study was anticipated to run for approximately 6 months but not to expected to exceed 9 months.The study period was 11 to 17 weeks for each subject.

Participant flow — Overall Study
MilestoneOverall Study
Started43
Gff mdi 14.4/9.6 µg40
Placebo mdi40
Completed33
Not completed10
Withdrew: Adverse event2
Withdrew: Lack of efficacy1
Withdrew: Withdrawal by subject4
Withdrew: Lost to follow-up1
Withdrew: Protocol criteria2

Outcome measures

PrimaryFEV1 AUC0-24 on Day 29

Forced Expiratory Volume in One Second (FEV1) Area Under the Curve (AUC)0-24 on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
FEV1 AUC0-24 on Day 29
LitersGFF MD (PT003)Placebo
FEV1 AUC0-24 on Day 290.166 (0.110 to 0.222)-0.083 (-0.143 to -0.024)
SecondaryFEV1 AUC12-24 on Day 29

FEV1 AUC12-24 on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
FEV1 AUC12-24 on Day 29
LitersGFF MD (PT003)Placebo
FEV1 AUC12-24 on Day 290.115 (0.055 to 0.175)-0.127 (-0.191 to -0.063)
SecondaryFEV1 AUC0-12 on Day 29

FEV1 AUC0-12 on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
FEV1 AUC0-12 on Day 29
LitersGFF MD (PT003)Placebo
FEV1 AUC0-12 on Day 290.216 (0.157 to 0.276)-0.039 (-0.103 to 0.025)
SecondaryPeak Change From Baseline in FEV1 on Day 29

Peak Change From Baseline in FEV1 following evening Dose on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
Peak Change From Baseline in FEV1 on Day 29
LitersGFF MD (PT003)Placebo
Peak Change From Baseline in FEV1 on Day 290.344 (0.275 to 0.412)0.050 (-0.023 to 0.124)
SecondaryPeak Change From Baseline in FEV1 on Day 29

Peak Change From Baseline in FEV1 following the morning dose on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
Peak Change From Baseline in FEV1 on Day 29
LitersGFF MD (PT003)Placebo
Peak Change From Baseline in FEV1 on Day 290.410 (0.338 to 0.482)0.134 (0.058 to 0.209)
SecondaryMorning Pre-Dose Trough FEV1 on Day 29

Morning Pre-Dose Trough FEV on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
Morning Pre-Dose Trough FEV1 on Day 29
LitersGFF MD (PT003)Placebo
Morning Pre-Dose Trough FEV1 on Day 290.130 (0.086 to 0.173)-0.012 (-0.058 to 0.033)
SecondaryMorning Pre-Dose Trough FEV1 on Day 30

Morning Pre-Dose Trough FEV1 on Day 30

Time frame:
Day 30
Reported as:
Mean · Liters
Morning Pre-Dose Trough FEV1 on Day 30
LitersGFF MD (PT003)Placebo
Morning Pre-Dose Trough FEV1 on Day 300.090 (0.032 to 0.148)-0.064 (-0.124 to -0.003)
SecondaryPeak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29

Peak Change from Baseline in Inspiratory Capacity (IC) following the evening dose on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 29
LitersGFF MD (PT003)Placebo
Peak Change From Baseline in Inspiratory Capacity (IC) Following the Evening Dose on Day 290.486 (0.369 to 0.603)0.105 (-0.019 to 0.229)
SecondaryPeak Change From Baseline in IC Following the Morning Dose on Day 29

Peak Change from Baseline in IC following the morning dose on Day 29

Time frame:
Day 29
Reported as:
Mean · Liters
Peak Change From Baseline in IC Following the Morning Dose on Day 29
LitersGFF MD (PT003)Placebo
Peak Change From Baseline in IC Following the Morning Dose on Day 290.543 (0.448 to 0.639)0.208 (0.106 to 0.310)

Adverse events

Collected over Adverse events were collected from the time the subject signed consent up to the follow-up phone call 7-14 days after last dose of study drug.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
GFF MDI PT003—1/40 (2.5%)1/40 (2.5%)
Placebo—1/40 (2.5%)6/40 (15%)
Most frequent serious events
Most frequent serious events
EventGFF MDI PT003Placebo
Abscess limbInfections and infestations0/401/40
GastroenteritisInfections and infestations1/400/40
Most frequent other events
Most frequent other events
EventGFF MDI PT003Placebo
DyspnoeaRespiratory, thoracic and mediastinal disorders0/402/40
Sinus CongestionRespiratory, thoracic and mediastinal disorders0/402/40
HypertenstionVascular disorders1/402/40

Baseline characteristics

The MITT Population was a subset of the ITT Population including the subjects who received treatment and had post-treatment efficacy data from both treatment periods.

Age, Continuous
Age, Continuous(Years)All Subjects
Mean61.3 ± 9.2
Sex: Female, Male
Sex: Female, Male(Participants)All Subjects
Female15
Male20
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Reisner C, Gottschlich G, Fakih F, Koser A, Krainson J, Delacruz L, Arora S, Feldman G, Pudi K, Siddiqui S, Orevillo C, Maes A, St Rose E, Martin U. 24-h bronchodilation and inspiratory capacity improvements with glycopyrrolate/formoterol fumarate via co-suspension delivery technology in COPD. Respir Res. 2017 Aug 18;18(1):157. doi: 10.1186/s12931-017-0636-4. PubMed 28821260 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2015 to primary completion in Jun 2015, 4 months.

Results were first posted in Apr 2017, 1 year 10 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 4 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 21, 2015
First posted
Jan 27, 2015
StartActual
Feb 1, 2015
Primary completionActual
Jun 1, 2015
CompletionActual
Jun 1, 2015
Results first posted
Apr 19, 2017
Last update
Jul 19, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 19, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02347085
Responsible party
Sponsor
First posted
Jan 27, 2015
Start date
Feb 1, 2015
Primary completion
Jun 1, 2015
Completion
Jun 1, 2015
Results posted
Apr 19, 2017
Last update
Jul 19, 2018

Study contacts

Colin Reisner, MD
study chair · Pearl Therapeutics

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Glycopyrrolate · Formoterol

Start the discussion